See you in Chicago!
Accelagen is proud to announce that Trent Wadford, our U.S. representative, will be attending the Chicago BioLife Summit on May 28, 2025, at the Renaissance Chicago Downtown Hotel. As a trusted partner for biotechs navigating today’s unpredictable clinical development landscape, Trent will be available to meet with attendees seeking strategic guidance, global insight, and solutions to help maximise the impact of their early-phase clinical programs.
A Perfect Event for In-Depth Conversations
The BioLife Summit series offers a uniquely intimate atmosphere, ideal for meaningful conversations that dive beyond surface-level introductions. After a successful experience at the Dallas Summit earlier this year, Accelagen is excited to once again engage with biotech leaders — this time in Chicago — to discuss how Australian clinical trials can accelerate progress, reduce costs, and open new paths to success.
“The conversations we had in Dallas were exactly the type we value most,” says Trent. “Focused, strategic, and centered around how to make every dollar raised go further for biotechs trying to bring life-saving innovations to market.”
Why the Australian Advantage Matters Now More Than Ever
In today’s volatile investment climate, biotech companies are under tremendous pressure to do more with less. Trent will be discussing how partnering with Accelagen for early-phase clinical trials in Australia can help sponsors maximise every investment dollar through:
- Up to 43.5% R&D Tax Incentive offered by the Australian government.
- Faster regulatory timelines compared to the U.S., getting programs into the clinic more quickly.
- Global data acceptance, with Australian trial results widely recognised by regulatory bodies like the FDA.
- A stable, efficient regulatory environment even as U.S. agencies face staffing cuts and increasing delays.
“The uncertainty around U.S. markets and regulatory processes in 2025 makes Australia an even smarter strategic choice,” says Trent. “Whether companies partner with us or another CRO in Australia, they need to know there’s a faster, more efficient path forward.”
Tailored Strategies for Every Biotech’s End Goals
What sets Accelagen apart is our commitment to aligning every clinical and regulatory strategy with the client’s long-term business goals. Trent will work with attendees to explore how Accelagen helps companies:
- Design trials based only on critical endpoints that support commercialization, licensing, or acquisition strategies.
- Maximise operational and financial efficiency.
- Avoid unnecessary steps that slow progress without delivering value to investors or future partners.
“We take the time to truly understand where a company wants to go,” explains Trent. “Then we build a clinical path that gets them there with precision.”
Meet with Trent at the BioLife Summit
Trent will be available for pre-arranged meetings on May 27 (afternoon and evening) as well as throughout the day on May 28 during the summit. While he’ll also attend speaker sessions to stay connected with industry trends, Trent is carving out ample time for one-on-one discussions with biotech leaders.
If you are a biotech executive looking for ways to accelerate your asset’s development, stretch your funding further, or better position your company for growth or acquisition, this is the conversation you cannot afford to miss.
Schedule Time with Trent
To set up a meeting before or during the event:
- Call/Text: (919) 607-0313
Email:[email protected]